Poxel ALD Treatment Update
Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy (ALD)
“Phase 2a clinical Proof-of-Concept biomarker study for PXL065 in adrenoleukodystrophy (ALD) now anticipated to start midyear, with results to follow in early 2023”
To read the press release:
